Tag: Innovative Medicines

South Korean company acquires AMPAC Fine Chemicals

SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.

Harvard researchers developed a new method to deliver insulin orally

Scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences have developed an oral delivery method that could dramatically transform the way in which diabetics keep their blood sugar levels in check.

Juvenescence receives $50 million to develop anti-aging therapies

Juvenescence Limited, a leader in the development of therapies to slow, halt or potentially reverse aging, has successfully raised $50 million in its Series A financing.

Vetter launches the Open Innovation Challenge

lab research
The purpose of the challenge is to develop innovative, future-focused and sustainable solutions for the injection of medicines that are even better streamlined to user needs than current methods.

Celltrion and Yonsei University Health System will develop new biopharmaceuticals

Celltrion signed an agreement with Yonsei University Health System on the joint development of Fc-Saxatilin, a candidate drug for ischemic strokes in a bid to develop new biopharmaceuticals for cerebrovascular diseases.

Eligo Bioscience received financing to strengthen its biotherapeutic platform

Eligo Bioscience, the French microbiome company, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge.

Cerenis Therapeutics and UNTHSC will jointly develop HDL-based pharma products

CERENIS Therapeutics, an international biopharmaceutical company dedicated to the development of HDL-based innovative therapies, signed a strategic partnership with the University of North Texas Health Science Center.

Novel medicines development company Brii Bio launches in China

drug development
Brii Bio, a Chinese company committed to serving patients’ needs and improving public health, announced its launch with significant partnerships and financing.

Synthorx obtains $63 million financing to develop novel protein therapeutics

The proceeds of the financing will be used to advance the company’s pipeline of Synthorin™ cytokines, including an IL-2 tuned specifically for activity on certain immune cells.

Evox Therapeutics upgrades its facilities at The Oxford Science Park

Evox Therapeutics, a leading exosome therapeutics company, announced it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities.

Sandoz and Pear Therapeutics will jointly develop digital therapeutics

digital drug
Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics.

Small biotech companies rule in development of microbiome-targeted therapeutics

According to leading data and analytics company GlobalData, large pharma firms are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology,

Arbutus and Roivant create Genevant Sciences to focus on RNA-based therapeutics

Arbutus Biopharma Corporation and Roivant Sciences entered into an agreement to launch Genevant Sciences, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics.

State Duma deputies propose to simplify registration of Russian medicines

The issues of legislative regulation and simplification of drug registration procedures were discussed by participants of the roundtable held on April 9 in the Russian State Duma.

Ferring buys a clinical microbiome company Rebiotix

lab research
This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.

IFAR is developing a life-extending drug

The scientists from IFAR, a Tomsk-based Russian company, found a way to use plant materials for producing a substance that extends human life.